性别对脊柱关节炎患者结局指标的影响是否相似?ASAS-perSpA研究结果
基于ASAS-perSpA研究中23个国家4185例脊柱关节炎(SpA)患者数据,分析性别与疾病活动度、功能和整体健康结局指标的关联。女性性别与更差的结局指标相关,但ASDAS仅在周围型SpA和银屑病关节炎中与性别相关,在中轴型SpA中无关联。因此ASDAS是中轴型SpA女性和男性的合适工具。
要点
- 女性性别与三个SpA亚型中更高的BASDAI独立相关,但幅度不同。
- 女性性别仅与周围型SpA和银屑病关节炎中更高的ASDAS相关,与中轴型SpA无关联。
- 女性性别与更高的ASAS HI和EQ-5D相关,各亚型间无差异。
核心结论
- 女性性别与SpA谱系中较不利的结局指标相关。
- 女性性别影响三个亚型的BASDAI,但ASDAS仅与周围型SpA和银屑病关节炎的性别相关,与中轴型SpA无关。
- 因此ASDAS是中轴型SpA女性和男性的合适工具。
研究设计与样本
- 分析ASAS-perSpA研究中23个国家4185例诊断为中轴型SpA、周围型SpA或银屑病关节炎患者的数据。
- 采用多水平多变量线性混合模型,校正相关混杂因素,并在存在相关交互作用时按疾病亚型分层。
主要发现
- 中轴型SpA、周围型SpA和银屑病关节炎患者分别占65%、10%和25%。
- 中轴型SpA更多见于男性(68%),周围型SpA和银屑病关节炎更多见于女性(分别为53%和52%)。
- 性别与疾病亚型在ASDAS、BASDAI和BASFI上存在显著交互作用。
- 女性性别与三个亚型中更高的BASDAI独立相关,幅度不同;仅与周围型SpA(β 0.36,95%CI 0.15至0.58)和银屑病关节炎(β 0.25,95%CI 0.12至0.38)中更高的ASDAS相关,与中轴型SpA无关联(β 0.016,95%CI -0.07至0.11)。
- 性别与CRP水平无关联;女性性别与更高的ASAS HI和EQ-5D相关,各亚型间无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the influence of gender on disease outcomes in patients with spondyloarthritis (SpA), including across SpA subtypes. METHODS: Data from 4185 patients of 23 countries with a diagnosis of axial SpA (axSpA), peripheral SpA (pSpA) or psoriatic arthritis (PsA) from the Assessment of SpondyloArthritis International Society (ASAS)-perSpA study were analysed. Associations between gender and disease activity (Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Score (BASDAI), C-reactive protein (CRP)), function (Bath Ankylosing Spondylitis Functional Index (BASFI)) and overall health (ASAS Health Index (ASAS HI), European Quality of Life Five Dimension (EQ-5D)) outcomes were investigated. Multilevel multivariable linear mixed models adjusted for relevant confounders (and stratified by disease subtype in case of a relevant interaction) were used. RESULTS: In total, 65%, 10% and 25% of patients had axSpA, pSpA and PsA, respectively. axSpA was more frequent in males (68%), whereas pSpA and PsA were more frequent in females (53% and 52%, respectively). A significant interaction between gender and disease subtype was found for ASDAS, BASDAI and BASFI. While being female independently contributed to higher BASDAI across the three disease subtypes (with varying magnitude), female gender was only associated with higher ASDAS in pSpA (β (95% CI): 0.36 (0.15 to 0.58)) and PsA (0.25 (0.12 to 0.38)) but not in axSpA (0.016 (-0.07 to 0.11)). No associations were observed between gender and CRP levels. Female gender was associated with higher ASAS HI and EQ-5D, without differences across disease subtype. CONCLUSION: Female gender is associated with less favourable outcome measures across the SpA spectrum. However, while female gender influences BASDAI across the three subtypes, ASDAS is associated with gender only in pSpA and PsA but not in axSpA. Therefore, ASDAS is an appropriate instrument both for females and males with axSpA.
引用
- Benavent D, Capelusnik D, Ramiro S, et al. Does gender influence outcome measures similarly in patients with spondyloarthritis? Results from the ASAS-perSpA study. RMD Open. 2022. PMID: 36096523. doi:10.1136/rmdopen-2022-002514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。